US
Weight-loss medications
Evidence-based guidance on weight-loss medications including GLP-1 receptor agonists like Wegovy, Ozempic, and Mounjaro. Find reliable information on efficacy, side effects, NHS availability, and how these medications work as part of a balanced approach to weight loss. Our content is developed by healthcare professionals and nutritionists to support informed decisions about medication-assisted weight loss in the UK.
Wegovy compatibility
Can you take Wegovy with osteoarthritis?
You can take Wegovy with osteoarthritis. The STEP 9 trial showed that Wegovy supported a reduction in knee pain and improved daily function.
Weight-loss medications
Wegovy pill vs Wegovy injection: which works better, and which is right for you?
The Wegovy injection produced an average weight loss of 14.9% in trials vs 13.6% for the Wegovy pill. The pill isn't yet available in the UK.
Mounjaro compatibility
Can you take Mounjaro with propranolol?
You can take Mounjaro alongside propranolol. The main considerations are added blood pressure effects and hidden low blood sugar warning signs.
Weight-loss medications
Can oral weight-loss medications help you maintain weight loss after Mounjaro or Wegovy?
ATTAIN-MAINTAIN trial: people who switched from Mounjaro or Wegovy injections to Foundayo kept 75-79% of their weight loss. Not yet approved in the UK.
Weight-loss medications
The Wegovy pill: what it is, how it works, and when it’s coming to the UK
The Wegovy pill (oral semaglutide 25 mg) is the first GLP-1 pill approved for weight loss. FDA-approved in the U.S., UK approved in June 2026.
Weight-loss medications
The Wegovy pill vs Foundayo: which oral GLP-1 medication is better for weight loss?
Wegovy pill vs Foundayo: 13.6% vs 11.2% average weight loss in trials. Wegovy pill needs an empty stomach; Foundayo can be taken any time.
Weight-loss medications
Oral weight-loss medications in the UK: a 2026 guide to the Wegovy pill, Foundayo, and Rybelsus
Three oral GLP-1 weight-loss pills compared. Wegovy pill (13.6%) and Foundayo (11.2%) expected in UK late 2026 and 2027; Rybelsus available now for type 2.
Weight-loss medications
Foundayo (orforglipron): what it is, how it works, and when it’s coming to the UK
Foundayo (orforglipron) is a daily GLP-1 pill for weight loss with no fasting requirements. FDA-approved April 2026. Average weight loss 11.2% at 72 weeks.
Weight-loss medications
Retatrutide vs Wegovy: which works better for weight loss?
Retatrutide produced 28.7% weight loss in trials vs Wegovy 7.2 mg's 20.7%. Retatrutide isn't UK-approved yet; Wegovy is the current option.
Weight-loss medications
Retatrutide side effects: what the trials show and how to manage them
Retatrutide's main side effects in trials: nausea (43%), heart rate increase of ~6.7 bpm, and dysesthesia (20.9%) at the 12 mg dose. Not yet UK-approved.
As seen on
As seen on
